Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) breast cancer study fully recruited
Published by Arron Aatkar, PhD

Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase II TRIFOUR trial, which is evaluating nadunolimab in combination with platinum-based chemotherapy, compared to chemotherapy alone, in triple negative breast cancer. The initial efficacy results are anticipated from mid-2025, potentially representing a near-term catalyst for the company.

The prior interim update from the Phase Ib dose-finding portion of the programme (n=15) were encouraging, showing an overall response rate of 60%, median progression-free survival of 6.6 months and overall survival of 12.8 months.

Latest

Industrials | Comment

Earnz (AIM: EARN) – Proposed acquisition of Zero Carbon Group

Industrials | Comment

Electro Optic Systems (ASX: EOS) announces US$45m order win

Financials | Comment

Revolut secures full UK banking licence

Healthcare | Comment

OSE Immunotherapeutics (PAR: OSE) confirms new CEO